EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)

Arndt Stahler iD, Beeke Hoppe, Il-Kang Na iD, Luisa Keilholz iD, Lothar Müller iD, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven iD, Ludwig Fischer von Weikersthal, Eray Goekkurt, Stefan Kasper, Andreas Jay Kind iD und 10 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.22.02582 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Arndt Stahler und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Cancer Immunology, Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humbo…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Consensus molecular subtypes (CMSs) were evaluated as prognostic and predictive biomarkers of patients with RAS wild-type metastatic colorectal cancer (mCRC) receiving fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab) after Pmab + mFOLFOX6 induction within the randomized phase II PanaMa trial. METHODS CMSs were determined in the safety set (ie, patients that received induction) and full analysis set (FAS; ie, randomly assigned patients who received maintenance) and correlated with median progression-free survival (PFS) and overall survival (OS) since the start of induction or maintenance treatment and objective response rates (ORRs). Hazard ratios (HRs) and 95% CI were calculated by univariate/multivariate Cox regression analyses. RESULTS Of 377 patients of the safety set, 296 (78.5%) had available CMS data: CMS1/2/3/4: 29 (9.8%)/122 (41.2%)/33 (11.2%)/112 (37.8%) and unclassifiable: 17 (5.7%). The CMSs were prognostic biomarkers in terms of PFS ( P < .0001), OS ( P < .0001), and ORR ( P = .02) since the start of induction treatment. In FAS patients (n = 196), with CMS2/4 tumors, the addition of Pmab to FU/FA maintenance therapy was associated with longer PFS (CMS2: HR, 0.58 [95% CI, 0.36 to 0.95], P = .03; CMS4: HR, 0.63 [95% CI, 0.38 to 1.03], P = .07) and OS (CMS2: HR, 0.88 [95% CI, 0.52 to 1.52], P = .66; CMS4: HR, 0.54 [95% CI, 0.30 to 0.96], P = .04). The CMS interacted significantly with treatment in terms of PFS (CMS2 v CMS1/3: P = .02; CMS4 v CMS1/3: P = .03) and OS (CMS2 v CMS1/3: P = .03; CMS4 v CMS1/3: P < .001). CONCLUSION The CMS had a prognostic impact on PFS, OS, and ORR in RAS wild-type mCRC. In PanaMa, Pmab + FU/FA maintenance was associated with beneficial outcomes in CMS2/4, whereas no benefit was observed in CMS1/3 tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansPanitumumabLeucovorinFluorouracilBiomarkersAntineoplastic Combined Chemotherapy Protocols

Substanzen

PanitumumabLeucovorinFluorouracilBiomarkers

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Cancer Immunology, Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • DKTK, German Cancer Consortium, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Center for Regenerative Therapies, Berlin, Germany.
  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, ECRC Experimental and Clinical Research Center, Berlin, Germany.
  • Oncology Practice UnterEms, Leer, Germany.
  • Department of Hematology and Oncology, Munich Hospital Neuperlach, Munich, Germany.

ORCID-Profile: Arndt Stahler, Il-Kang Na, Luisa Keilholz, Lothar Müller, Ullrich Graeven, Andreas Jay Kind, Annika Kurreck, Annabel Helga Sophie Alig, Anke Reinacher-Schick, Volker Heinemann, Sebastian Stintzing, Dominik Paul Modest

Zitieren

APA

Stahler, A., Hoppe, B., Na, I. K., Keilholz, L., Müller, L., Karthaus, M., Fruehauf, S., Graeven, U., Fischer von Weikersthal, L., Goekkurt, E., Kasper, S., Kind, A. J., Kurreck, A., Alig, A. H. S., Held, S., Reinacher-Schick, A., Heinemann, V., Horst, D., Jarosch, A., …, & Modest, D. P. (2023). Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212). Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02582

Vancouver

Stahler A, Hoppe B, Na IK, Keilholz L, Müller L, Karthaus M, et al. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212). Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02582

BibTeX
@article{Stahler2023,
  author = {Stahler, Arndt and Hoppe, Beeke and Na, Il-Kang and Keilholz, Luisa and Müller, Lothar and Karthaus, Meinolf and Fruehauf, Stefan and Graeven, Ullrich and Fischer von Weikersthal, Ludwig and Goekkurt, Eray and Kasper, Stefan and Kind, Andreas Jay and Kurreck, Annika and Alig, Annabel Helga Sophie and Held, Swantje and Reinacher-Schick, Anke and Heinemann, Volker and Horst, David and Jarosch, Armin and Stintzing, Sebastian and Trarbach, Tanja and Modest, Dominik Paul},
  title = {Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.22.02582}
}
Kostenlos starten →